These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 36200548)

  • 1. Impact of heart failure on the clinical profile and outcomes in patients with atrial fibrillation treated with rivaroxaban. Data from the EMIR study.
    Anguita Sánchez M; Marín F; Masjuan J; Cosín-Sales J; Vázquez Rodríguez JM; Barrios V; Barón-Esquivias G; Lekuona I; Pérez-Cabeza AI; Freixa-Pamias R; Parra Jimenez FJ; Monzer Khanji Khatib M; Rafols Priu C; Sanmartín Fernández M
    Cardiol J; 2022; 29(6):936-947. PubMed ID: 36200548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes and predictive value of the 2MACE score in patients with atrial fibrillation treated with rivaroxaban in a prospective, multicenter observational study: The EMIR study.
    Sanmartín Fernández M; Anguita Sánchez M; Arribas F; Barón-Esquivias G; Barrios V; Cosin-Sales J; Esteve-Pastor MA; Freixa-Pamias R; Lekuona I; Pérez-Cabeza AI; Ureña I; Vázquez Rodríguez JM; Rafols Priu C; Marin F
    Cardiol J; 2022; 29(4):601-609. PubMed ID: 35621092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Factors associated with disease progression in patients with atrial fibrillation and heart failure anticoagulated with rivaroxaban.
    Manito N; Cepeda-Rodrigo JM; Farré N; Castillo Orive M; Galve E; Jiménez-Candil J; García-Pinilla JM; López Sánchez ES; Rafols C; Gómez Doblas JJ
    Clin Cardiol; 2024 Feb; 47(2):e24189. PubMed ID: 38018889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adverse Clinical Outcomes and Associated Predictors in Rivaroxaban-Treated Atrial Fibrillation Patients With Renal Impairment.
    Rivera-Caravaca JM; Anguita Sanchez M; Sanmartín Fernández M; Rafols C; Barón-Esquivias G; Arribas Ynsaurriaga F; Freixa-Pamias R; Lekuona Goya I; Vázquez Rodríguez JM; Pérez-Cabeza AI; Cosín-Sales J; Ureña Montilla I; Álvarez-Vieitez Blanco A; Marín F
    Am J Cardiol; 2023 Sep; 203():122-127. PubMed ID: 37487406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical profile and outcomes in very elderly patients with atrial fibrillation anticoagulated with rivaroxaban: data from the EMIR study.
    Marín F; Sánchez MA; Lekuona I; Fernández MS; Barrios V; Muñoz CP; Cosín-Sales J; Pérez Cabeza AI; Schilling VR; Priu CR; Orenes-Piñero E; Esteve-Pastor MA
    J Geriatr Cardiol; 2024 Jul; 21(7):723-732. PubMed ID: 39183954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes and factors associated with mortality in patients with atrial fibrillation and heart failure: FARAONIC study.
    Gómez Doblas JJ; Cepeda-Rodrigo JM; Agra Bermejo R; Blanco Labrador E; Blasco MT; Carrera Izquierdo M; Lekuona I; Recio Mayoral A; Rafols C; Manito N
    Clin Cardiol; 2023 Nov; 46(11):1390-1397. PubMed ID: 37596723
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heart failure subtypes and thromboembolic risk in patients with atrial fibrillation: The PREFER in AF - HF substudy.
    Siller-Matula JM; Pecen L; Patti G; Lucerna M; Kirchhof P; Lesiak M; Huber K; Verheugt FWA; Lang IM; Renda G; Schnabel RB; Wachter R; Kotecha D; Sellal JM; Rohla M; Ricci F; De Caterina R;
    Int J Cardiol; 2018 Aug; 265():141-147. PubMed ID: 29706429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF).
    Rohla M; Weiss TW; Pecen L; Patti G; Siller-Matula JM; Schnabel RB; Schilling R; Kotecha D; Lucerna M; Huber K; De Caterina R; Kirchhof P
    BMJ Open; 2019 Mar; 9(3):e022478. PubMed ID: 30928922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The HAS-BLED score has better prediction accuracy for major bleeding than CHADS2 or CHA2DS2-VASc scores in anticoagulated patients with atrial fibrillation.
    Roldán V; Marín F; Manzano-Fernández S; Gallego P; Vílchez JA; Valdés M; Vicente V; Lip GY
    J Am Coll Cardiol; 2013 Dec; 62(23):2199-204. PubMed ID: 24055744
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rivaroxaban for the prevention of outcomes in patients with atrial fibrillation in clinical practice: an indirect comparison of national and international registries.
    Marin F; Fernández MS; Lekuona I; Arribas F; Barón-Esquivias G; Barrios V; Cosin-Sales J; Freixa-Pamias R; Masjuan J; Pérez-Cabeza AI; Schilling VR; Vázquez Rodríguez JM; Priu CR; Sánchez MA
    J Comp Eff Res; 2022 Nov; 11(16):1173-1184. PubMed ID: 36148923
    [No Abstract]   [Full Text] [Related]  

  • 11. Characteristics and outcomes of atrial fibrillation patients with or without specific symptoms: results from the PREFER in AF registry.
    Bakhai A; Darius H; De Caterina R; Smart A; Le Heuzey JY; Schilling RJ; Zamorano JL; Shah M; Bramlage P; Kirchhof P
    Eur Heart J Qual Care Clin Outcomes; 2016 Oct; 2(4):299-305. PubMed ID: 29474715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of patients with atrial fibrillation on oral anticoagulation with and without heart failure: the ETNA-AF-Europe registry.
    Schnabel RB; Ameri P; Siller-Matula JM; Diemberger I; Gwechenberger M; Pecen L; Manu MC; Souza J; De Caterina R; Kirchhof P
    Europace; 2023 Aug; 25(9):. PubMed ID: 37713182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. XaMINA: A Real-World, Prospective, Observational Study of Treatment-Naïve Patients Treated with Rivaroxaban for Stroke Prevention in Atrial Fibrillation in Asia.
    Liu PY; Choi EK; Kim TS; Kuo JY; Lee JM; On YK; Park SW; Park HW; Shin DG; Wang L; Yen HW; Lee MH;
    Adv Ther; 2022 Jul; 39(7):3316-3333. PubMed ID: 35616848
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-World Outcomes of Rivaroxaban Treatment in Patients with Both Nonvalvular Atrial Fibrillation and a History of Ischemic Stroke/Transient Ischemic Attack.
    Minematsu K; Ikeda T; Ogawa S; Kitazono T; Nakagawara J; Miyamoto S; Murakawa Y; Takeichi M; Kidani Y; Okayama Y; Sunaya T; Sato S; Yamanaka S
    Cerebrovasc Dis; 2019; 48(1-2):53-60. PubMed ID: 31578012
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk Levels and Adverse Clinical Outcomes Among Patients With Nonvalvular Atrial Fibrillation Receiving Oral Anticoagulants.
    Lip GYH; Murphy RR; Sahiar F; Ingall TJ; Dhamane AD; Ferri M; Hlavacek P; Preib MT; Keshishian A; Russ C; Rosenblatt L; Yuce H; Deitelzweig S
    JAMA Netw Open; 2022 Aug; 5(8):e2229333. PubMed ID: 36044214
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness and safety of rivaroxaban in nonvalvular atrial fibrillation: data from a contemporary Spanish registry.
    Caro Martinez C; Cerezo Manchado JJ; Flores Blanco PJ; Elvira Ruíz G; Albendín Iglesias H; Lova Navarro A; Arregui Montoya F; García Alberola A; Andrés Pascual Figal D; Bailén Lorenzo JL; Navarro-Almenzar B; García-Candel F; Manzano Fernández S
    Curr Med Res Opin; 2019 Aug; 35(8):1463-1471. PubMed ID: 30912682
    [No Abstract]   [Full Text] [Related]  

  • 17. Clinical Risk Factors of Thromboembolic and Major Bleeding Events for Patients with Atrial Fibrillation Treated with Rivaroxaban in Japan.
    Miyamoto S; Ikeda T; Ogawa S; Kitazono T; Nakagawara J; Minematsu K; Murakawa Y; Iwashiro S; Takeichi M; Kidani Y; Okayama Y; Sunaya T; Sato S; Yamanaka S
    J Stroke Cerebrovasc Dis; 2020 Apr; 29(4):104584. PubMed ID: 31983518
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bleeding outcomes associated with rivaroxaban and dabigatran in patients treated for atrial fibrillation: a systematic review and meta-analysis.
    Bundhun PK; Soogund MZ; Teeluck AR; Pursun M; Bhurtu A; Huang WQ
    BMC Cardiovasc Disord; 2017 Jan; 17(1):15. PubMed ID: 28056795
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of the CHA2DS2-VASc Score in Predicting Ischemic Stroke, Thromboembolism, and Death in Patients With Heart Failure With and Without Atrial Fibrillation.
    Melgaard L; Gorst-Rasmussen A; Lane DA; Rasmussen LH; Larsen TB; Lip GY
    JAMA; 2015 Sep; 314(10):1030-8. PubMed ID: 26318604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of Rivaroxaban vs Apixaban With Major Ischemic or Hemorrhagic Events in Patients With Atrial Fibrillation.
    Ray WA; Chung CP; Stein CM; Smalley W; Zimmerman E; Dupont WD; Hung AM; Daugherty JR; Dickson A; Murray KT
    JAMA; 2021 Dec; 326(23):2395-2404. PubMed ID: 34932078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.